Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Interest & Investment Income (2020 - 2025)

UroGen Pharma's Interest & Investment Income history spans 6 years, with the latest figure at $903000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 67.16% year-over-year to $903000.0; the TTM value through Dec 2025 reached $5.3 million, down 38.94%, while the annual FY2025 figure was $5.3 million, 38.94% down from the prior year.
  • Interest & Investment Income reached $903000.0 in Q4 2025 per URGN's latest filing, down from $979000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q4 2024 to a low of $2000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $981157.9, with a median of $903000.0 recorded in 2025.
  • Peak YoY movement for Interest & Investment Income: tumbled 92.68% in 2021, then soared 31400.0% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $96000.0 in 2021, then soared by 318.75% to $402000.0 in 2022, then surged by 282.59% to $1.5 million in 2023, then surged by 78.8% to $2.8 million in 2024, then crashed by 67.16% to $903000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Interest & Investment Income are $903000.0 (Q4 2025), $979000.0 (Q3 2025), and $1.3 million (Q2 2025).